| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728214.2015.1051467 |
| P698 | PubMed publication ID | 26021342 |
| P50 | author | Marianna Silletta | Q114405675 |
| Marco Imperatori | Q103825783 | ||
| Daniele Santini | Q37837892 | ||
| Giuseppe Tonini | Q37838300 | ||
| Bruno Vincenzi | Q37838310 | ||
| P2093 | author name string | Eleonora Marrucci | |
| P2860 | cites work | Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive | Q24306328 |
| Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 | ||
| A comprehensive pathway map of epidermal growth factor receptor signaling | Q24672490 | ||
| Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity | Q26992272 | ||
| Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer | Q27320322 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells | Q27851718 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Defining the role of mTOR in cancer | Q28235431 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| The Met tyrosine kinase receptor in development and cancer | Q28263626 | ||
| Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275 | Q28342649 | ||
| Principles of CDK regulation | Q29547820 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| The biology of vascular endothelial growth factor | Q29615946 | ||
| Cellular functions regulated by Src family kinases | Q29616038 | ||
| Fibroblast growth factor signalling: from development to cancer | Q29616827 | ||
| Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors | Q52297317 | ||
| Frequent amplification of the c-met gene in scirrhous type stomach cancer. | Q53486015 | ||
| Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. | Q54341358 | ||
| A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. | Q54390371 | ||
| A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. | Q54604759 | ||
| Aurora kinase A in Barrett's carcinogenesis. | Q54660630 | ||
| Early HER2 dysregulation in gastric and oesophageal carcinogenesis | Q58003579 | ||
| Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma | Q58614911 | ||
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors | Q33387187 | ||
| Phase II study of sunitinib as second-line treatment for advanced gastric cancer | Q33389519 | ||
| Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study | Q33410627 | ||
| Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Gr | Q33435794 | ||
| Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study | Q33628794 | ||
| Aurora kinase inhibitors--rising stars in cancer therapeutics? | Q33647643 | ||
| Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. | Q33942266 | ||
| A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma | Q33944281 | ||
| Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. | Q33990928 | ||
| VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo | Q34300737 | ||
| Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer | Q34311116 | ||
| Review of epidermal growth factor receptor biology | Q34320636 | ||
| The ErbB/HER receptor protein-tyrosine kinases and cancer | Q34322472 | ||
| Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts | Q34349048 | ||
| HGF rescues colorectal cancer cells from EGFR inhibition via MET activation | Q34550898 | ||
| Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 | ||
| Aurora kinases | Q34557680 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| Identification of c-Src tyrosine kinase substrates using mass spectrometry and peptide microarrays. | Q34807910 | ||
| Identification of c-Src tyrosine kinase substrates in platelet-derived growth factor receptor signaling | Q34994048 | ||
| Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer | Q35032328 | ||
| Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer | Q35069652 | ||
| Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression | Q35201636 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase | Q35676802 | ||
| PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors | Q35838565 | ||
| A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets | Q35878807 | ||
| FGFR2 gene amplification and clinicopathological features in gastric cancer | Q35879874 | ||
| Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. | Q35927364 | ||
| Aurora-A: the maker and breaker of spindle poles | Q36917445 | ||
| K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase | Q36930426 | ||
| Review of docetaxel in the treatment of gastric cancer | Q37052880 | ||
| The aurora kinase A regulates GSK-3beta in gastric cancer cells | Q37096754 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia | Q37341585 | ||
| Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line | Q37361549 | ||
| HDM2 regulation by AURKA promotes cell survival in gastric cancer | Q37626244 | ||
| Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer | Q37709811 | ||
| Targeting the human EGFR family in esophagogastric cancer | Q37862077 | ||
| Anti-HER agents in gastric cancer: from bench to bedside | Q37885725 | ||
| Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. | Q38161727 | ||
| HER2 expression and PI3K-Akt pathway alterations in gastric cancer. | Q38181377 | ||
| Molecular pathways: CDK4 inhibitors for cancer therapy | Q38209308 | ||
| Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress | Q38266342 | ||
| FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival | Q38438387 | ||
| Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification | Q38953867 | ||
| Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-β signaling | Q39071833 | ||
| FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. | Q39181047 | ||
| MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells | Q39413378 | ||
| MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo | Q39733225 | ||
| Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells | Q40006240 | ||
| AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis | Q40118416 | ||
| AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor | Q40132585 | ||
| A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer | Q40209085 | ||
| The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function | Q40248512 | ||
| PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. | Q40259716 | ||
| The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases | Q40365711 | ||
| Knockdown of EGFR inhibits growth and invasion of gastric cancer cells | Q42181490 | ||
| Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer | Q43576000 | ||
| Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer | Q44764084 | ||
| On the merits and limitations of whole-brain radiation therapy | Q48265972 | ||
| Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 479-493 | |
| P577 | publication date | 2015-05-28 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging kinase inhibitors of the treatment of gastric cancer | |
| P478 | volume | 20 |
| Q37442586 | Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases |
| Q55240402 | Di-2-pyridylhydrazone Dithiocarbamate Butyric Acid Ester Exerted Its Proliferative Inhibition against Gastric Cell via ROS-Mediated Apoptosis and Autophagy. |
| Q91641140 | DpdtC-Induced EMT Inhibition in MGC-803 Cells Was Partly through Ferritinophagy-Mediated ROS/p53 Pathway |
| Q102144641 | The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer |
| Q26801532 | The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs |
| Q36294199 | miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer |
Search more.